0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover294.02%IV-100.94%PremiumJan 17, 2025Expiry Date7.54Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7559Delta0.0627Gamma0.93Leverage Ratio-0.0397Theta-0.0057Rho-0.70Eff Leverage0.0054Vega
Vir Biotechnology Stock Discussion
US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
*************************************
REVERSE...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran
No comment yet